These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 19298346)

  • 21. Epigenetic markers as promising prognosticators for bladder cancer.
    Kim YK; Kim WJ
    Int J Urol; 2009 Jan; 16(1):17-22. PubMed ID: 18721202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of invasive bladder cancers: histological and molecular markers.
    Liebert M; Seigne J
    Semin Urol Oncol; 1996 May; 14(2):62-72. PubMed ID: 8734733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of molecular markers for prognostication and outcome in invasive bladder cancer.
    Gakis G; Schwentner C; Todenhöfer T; Stenzl A
    BJU Int; 2012 Jul; 110(2):233-7. PubMed ID: 22233187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Editorial Comment to Cancer death from non-muscle invasive bladder cancer: Report of the Japanese Urological Association of data from the 1999-2001 registry in Japan.
    Koga F
    Int J Urol; 2010 Nov; 17(11):913. PubMed ID: 20969638
    [No Abstract]   [Full Text] [Related]  

  • 25. Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.
    Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Hirano M; Hayashida K; Mizumukai E; Nanaura H; Honda N
    Oncol Rep; 2007 Nov; 18(5):1183-7. PubMed ID: 17914570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
    Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
    BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
    Vasala K; Pääkko P; Turpeenniemi-Hujanen T
    Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.
    deVere White RW; Katz MH; Steinberg GD
    J Urol; 2009 May; 181(5):1994-7. PubMed ID: 19286209
    [No Abstract]   [Full Text] [Related]  

  • 29. P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells.
    Mandeville JA; Silva Neto B; Vanni AJ; Smith GL; Rieger-Christ KM; Zeheb R; Loda M; Libertino JA; Summerhayes IC
    BJU Int; 2008 Dec; 102(11):1707-14. PubMed ID: 18990147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    de Reijke TM
    Eur Urol; 2009 Jun; 55(6):1395-6. PubMed ID: 19193488
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative promoter methylation analysis of p53 target genes in urogenital cancers.
    Christoph F; Hinz S; Weikert S; Kempkensteffen C; Schostak M; Miller K; Schrader M
    Urol Int; 2008; 80(4):398-404. PubMed ID: 18587251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic impact of tumor markers in bladder cancer surveillance.
    Hong YM; Loughlin KR
    Urology; 2008 Jan; 71(1):131-5. PubMed ID: 18242381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
    Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
    Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.
    Dumache R; David D; Kaycsa A; Minciu R; Negru S; Puiu M
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):163-7. PubMed ID: 21682190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.
    Berggren de Verdier PJ; Kumar R; Adolfsson J; Larsson P; Norming U; Onelöv E; Wijkström H; Steineck G; Hemminki K
    Scand J Urol Nephrol; 2006; 40(5):363-9. PubMed ID: 17060081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary bladder tumor markers.
    Lokeshwar VB; Selzer MG
    Urol Oncol; 2006; 24(6):528-37. PubMed ID: 17138134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology.
    Kawauchi S; Sakai H; Ikemoto K; Eguchi S; Nakao M; Takihara H; Shimabukuro T; Furuya T; Oga A; Matsuyama H; Takahashi M; Sasaki K
    Hum Pathol; 2009 Dec; 40(12):1783-9. PubMed ID: 19733894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary markers in the detection of bladder cancer: what's new?
    Nielsen ME; Schaeffer EM; Veltri RW; Schoenberg MP; Getzenberg RH
    Curr Opin Urol; 2006 Sep; 16(5):350-5. PubMed ID: 16905981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Markers of prognosis in superficial bladder cancer.
    Fradet Y
    Semin Urol; 1992 Feb; 10(1):28-38. PubMed ID: 1565901
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.